Loading clinical trials...

Diagnostic Value of Ultralow-dose Computed Tomography for the Detection of Pulmonary Nodules and Lung Parenchym Alterations Compared to Standard-dose CT | Clinical Trials | Clareo Health

UNKNOWNNA

Diagnostic Value of Ultralow-dose Computed Tomography for the Detection of Pulmonary Nodules and Lung Parenchym Alterations Compared to Standard-dose CT

NCT02468609•Cantonal Hospital of St. Gallen

View on ClinicalTrials.gov

Summary

To investigate the diagnostic value of ultralow-dose computed tomography in the detection of pulmonary nodules and lung parenchym alterations (e.g. emphysema) compared to standard-dose-CT.

Eligibility

Age

18 - 90 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•planned normal dose-CT by clinical indication at our institution
•obtained informed consent

Exclusion Criteria

•planned lowdose-CT by clinical indication at institution
•no informed consent obtained
•age \< 18 years
•pregnancy

Locations (1)

Klinik für Radiologie und Nuklearmedizin

Sankt Gallen, Switzerland

Key Dates

Start Date

January 1, 2015

Primary Completion Date

December 1, 2016

Completion Date

December 1, 2016

Last Updated

January 27, 2016

Enrollment

500

ESTIMATED participants

Conditions

Multiple Pulmonary NodulesPulmonary Emphysema

Interventions

Ultralow-Dose-CT

RADIATION

Contacts

Michael A Messerli, MD

CONTACT

0041 71 494 66 66 Michael.Messerli@kssg.ch

Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency

NCT02796937

Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency

View study

COMPLETEDPHASE2

PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT00683722

Pulmonary Disease, Chronic ObstructivePulmonary Emphysema+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 27, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Diagnostic Value of Ultralow-dose Computed Tomography for the Detection of Pulmonary Nodules and Lung Parenchym Alterations Compared to Standard-dose CT

Inclusion Criteria

Exclusion Criteria

Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency

PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Implantation of Endobronchial Valves Versus Intrabronchial Valves in Patients With Severe Heterogeneous Emphysema

A Real-world Study for Patients With Multiple Pulmonary Ground-glass Nodules

Prediction Model for Multiple Pulmonary Nodules

Evaluate the Utility of the ProLung China Test in the Diagnosis of Lung Cancer